Novartis Receives EU Approval for Infliximab Biosimilar Zessly

ZURICH (Reuters)—Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases. Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult and pediatric Crohn’s disease, adult and pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis,... [Read More]

Source: The Rheumatologist - May 30, 2018 Category: Rheumatology Authors: Reuters Staff Tags: Drug Updates EU approval infliximab biosimilar Novartis Zessly Source Type: research